Coherus Reveals Sales Have Started Piling In On Pegfilgrastim

 
• By Aidan Fry

Projected sales of around $37 million in the first three months after launch of its Udenyca biosimilar of Amgen’s Neulasta pegfilgrastim brand in the US have put Coherus on an initial track towards recouping its investment in development.

MoneyStack
Coherus has needed less than three months to generate significant US sales from its Udenyca pegfilgrastim biosimilar • Source: Shutterstock

More from Biosimilars

More from Products